The Value and Deliverables of Medical Affairs: Affiliate Perspectives and Future Expectations.

Autor: Farrington AD; Lundbeck Pharma A/S, Business Area North, Medical, Valby, Denmark., Frøstrup AG; Pfizer Denmark, Medical Affairs, Ballerup, Denmark. annegrete.frostrup@pfizer.com., Dahl P; AstraZeneca A/S, Medical Affairs, Copenhagen, Denmark.
Jazyk: angličtina
Zdroj: Pharmaceutical medicine [Pharmaceut Med] 2023 Nov; Vol. 37 (6), pp. 417-424. Date of Electronic Publication: 2023 Oct 03.
DOI: 10.1007/s40290-023-00501-y
Abstrakt: The Medical Affairs (MA) function in pharmaceutical companies creates a unique opportunity to ensure the internal linkage between Research & Development (R&D) and Commercial/Marketing functions, in addition to managing external scientific engagements with multiple stakeholders across life-science ecosystems. In recognition of the strategic value of MA, the objective of this paper is to share a comprehensive set of practical examples of the main deliverables within the MA function in the affiliate and align these with the two distinct phases; pre- and post-launch, respectively. We believe that an information gap currently exists in the available literature on these matters addressing practical aspects and examples beyond visionary, strategic thinking. Based on this contribution, further opportunities within MA can be discussed. In addition, we share our thoughts and considerations on future advancements in the role.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: